Molecular sleuthing
Simple blood tests may spot lymphomas months earlier than traditional biopsies, offering patients faster pathways to diagnosis.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in…
Combining a DNA-damage drug with immunotherapy shows manageable safety in advanced lung and head cancers, opening new combination possibilities.
Near-term implementable findingMinimal residual disease guided treatment approaches in non-Hodgkin…
Blood-based tests now predict treatment outcomes in lymphoma better than imaging, helping doctors tailor therapy intensity to individual risk.
Underserved or high-risk populationsStem cell transplantation and gene therapy for telomere biology disorders
Gentler transplant approaches and emerging gene therapies offer patients with telomere disorders new hope for safer, longer-lasting remissions.
Standard additionThe Evolution of Chimeric Antigen Receptor T-Cell, Bispecific…
Multiple myeloma treatments are rapidly evolving beyond traditional options, with personalized sequencing strategies being tested across all disease stages.